Dogwood Therapeutics, Inc (NASDAQ:DWTX) Short Interest Up 78.9% in August

Dogwood Therapeutics, Inc (NASDAQ:DWTX) was the recipient of a significant growth in short interest in the month of August. As of August 31st, there was short interest totaling 89,398 shares, a growth of 78.9% from the August 15th total of 49,958 shares. Based on an average daily trading volume, of 87,927 shares, the short-interest ratio is presently 1.0 days. Currently, 0.3% of the shares of the company are short sold.

Dogwood Therapeutics Trading Down 1.7%

NASDAQ:DWTX traded down $0.03 during mid-day trading on Wednesday, hitting $1.70. 84,275 shares of the company’s stock were exchanged, compared to its average volume of 77,281. Dogwood Therapeutics has a fifty-two week low of $1.28 and a fifty-two week high of $9.50. The firm has a market capitalization of $57.79 million, a P/E ratio of -0.19 and a beta of 1.81. The company has a 50 day simple moving average of $1.90 and a 200-day simple moving average of $1.93.

Dogwood Therapeutics (NASDAQ:DWTX) last announced its earnings results on Thursday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.20). As a group, analysts expect that Dogwood Therapeutics will post -0.67 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Dogwood Therapeutics in a research note on Friday, July 24th. HC Wainwright reiterated a “buy” rating on shares of Dogwood Therapeutics in a research report on Wednesday, September 2nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Dogwood Therapeutics presently has an average rating of “Hold” and an average target price of $12.00.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.